Mersana Therapeutics buy Guggenheim
Start price
16.05.25
/
50%
€0.31
Target price
16.05.26
€4.46
Performance (%)
-14.13%
End price
17.05.26
-
Summary
This prediction is currently being closed. The prediction for Mersana Therapeutics disappoints with a performance of -14.13%. Guggenheim has a follow-up prediction for Mersana Therapeutics where he still thinks Mersana Therapeutics is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Mersana Therapeutics | - | - | - |
| iShares Core DAX® | -2.796% | -1.396% | -0.221% |
| iShares Nasdaq 100 | -6.352% | -0.407% | 28.998% |
| iShares Nikkei 225® | -6.943% | -0.275% | 48.214% |
| iShares S&P 500 | -3.410% | 0.396% | 20.281% |
Comments by Guggenheim for this prediction
In the thread Mersana Therapeutics diskutieren
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $5.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
In the thread Trading Mersana Therapeutics
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten